SCHEMBL3742601

SCHEMBL3742601

CC(NCc1ccc(C#CC(C)(C)C(=O)O)c(O)c1)c1cccc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 3/20 0.41
POLB P06746 1/20 0.40
EPHX2 P34913 2/20 0.39
ACP3 P15309 1/20 0.38
OPRM1 P35372 2/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
CYP2D6 P10635 2/20 0.38
MLNR O43193 1/20 0.38
ABCB11 O95342 1/20 0.38
ADRB1 P08588 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38
DRD2 P14416 1/20 0.38
ADRA2C P18825 1/20 0.38
CHRM3 P20309 1/20 0.38
GLRA1 P23415 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2C P28335 1/20 0.38
AVPR2 P30518 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13040798 0.89 POLB (0.38) CASRPOLBEPHX2ACP3OPRM1
SCHEMBL3738660 0.88 CASR (0.44) CASRPOLBACP3OPRM1OPRD1
SCHEMBL3738667 0.88 CASR (0.44) CASRPOLBACP3OPRM1OPRD1
SCHEMBL3731974 0.85 CASR (0.43) CASRPOLBEPHX2ACP3OPRM1
SCHEMBL3729564 0.85 CASR (0.43) CASRPOLBEPHX2ACP3OPRM1
SCHEMBL3732021 0.85 ACP3 (0.44) CASRPOLBEPHX2ACP3CYP2D6
SCHEMBL3739123 0.78 CASR (0.42) CASRPOLBACP3OPRM1OPRD1
SCHEMBL3739117 0.78 CASR (0.42) CASRPOLBACP3OPRM1OPRD1
SCHEMBL13077651 0.76 CASR (0.48) CASRPOLBACP3OPRM1OPRD1
SCHEMBL13077970 0.75 CASR (0.53) CASRPOLBEPHX2ACP3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US claimed
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES C1R, C3AR1, PTH1R CASR 5/4885POLB 3993/4885EPHX2 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.